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Summary
Mycobacterium bovis, the causative agent of tuberculosis in animals, has a broad
host range, including humans. Historically, public health concerns prompted pro-
grams to eradicate tuberculosis from cattle in many nations. Eradication efforts
decreased the prevalence of bovine tuberculosis; nevertheless, some countries
encountered significant obstacles, not least of which was a wildlife reservoir of M.
bovis. Efforts to decrease the size of the affected wildlife populations have neither
eliminated disease nor eliminated transmission to cattle. Consequently, the use of
a vaccine for wildlife is being explored. The vaccine most studied is M. bovis BCG,
an attenuated live vaccine, first developed 100 years ago. The most efficient and
effective means of vaccinating wildlife will be an oral vaccine. White-tailed deer in
Michigan, USA, constitute a reservoir of M. bovis. White-tailed deer are a popular
game species, and as such, represent a food animal to many hunters. BCG persis-
tence in deer tissues could result in human exposure to BCG. Although non-path-
ogenic, BCG exposure could induce false-positive skin test results, confounding
the central component of public health surveillance for TB. The objective of the
present study in white-tailed deer was to evaluate persistence of lipid-encapsu-
lated BCG and a liquid suspension of BCG after oral administration at two differ-
ent dosages. Vaccine was not recovered at any time after oral consumption of a
bait containing a single dose (1 9 108 CFU) of lipid-encapsulated BCG. How-
ever, persistence was consistent in deer consuming 10 lipid-encapsulated baits
(1 9 109 CFU), with BCG recovered from at least one deer at 1, 3, 6, 9 and
12 months after consumption. Persistence of up to 9 months was seen in deer
vaccinated with orally with a liquid suspension. Persistence of BCG was limited to
lymphoid tissue and never found in samples of muscle collected at each time
point. Although the risk of exposure to hunters is low, BCG persistence should be
considered prior to field use in white-tailed deer.
Introduction
Mycobacterium bovis is the causative agent of tuberculosis
in cattle and an important zoonotic pathogen. It has a
broad host range, including most mammals, and can cause
tuberculosis in humans that is clinically indistinguishable
from disease caused by Mycobacterium tuberculosis. Histori-
cally, public health concerns posed by potential transmis-
sion of M. bovis from cattle to humans prompted many
countries to implement national programs to eradicate
tuberculosis from cattle. Eradication campaigns have gener-
ally been successful in decreasing the prevalence of bovine
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tuberculosis; nevertheless, some countries have encoun-
tered significant obstacles. One factor responsible for falter-
ing eradication campaigns has been the presence of a
wildlife reservoir of M. bovis. In most cases, wildlife origi-
nally acquired tuberculosis from cattle; however, M. bovis is
now spilling back from wildlife to cattle, impeding the
progress of eradication (Daszak et al., 2000; Miller and
Kaneene, 2006). In an effort to reduce wildlife to cattle
transmission of M. bovis, some countries are investigating
the possible role of wildlife vaccination (Aldwell et al.,
1995; Ballesteros et al., 2009). Oral administration of a
vaccine is the most practical and cost-effective means of
vaccinating wildlife. Illustratively, oral rabies vaccines have
been used to successfully vaccinate foxes, raccoons and
other wildlife against rabies (MacInnes et al., 2001; Rosatte
et al., 2007).
In 1994, a hunter-killed white-tailed deer (Odocoileus
virginianus) in Michigan was diagnosed with tuberculosis
due to M. bovis (Schmitt et al., 1997). Subsequent surveys
identified a focus of M. bovis in free-ranging white-tailed
deer in north-east Michigan (O’Brien et al., 2001, 2002).
This represented the first known reservoir of M. bovis in
free-ranging wildlife in the United States (US), the first
known epizootic of tuberculosis in white-tailed deer and a
significant impediment to the US effort to eradicate bovine
tuberculosis from livestock. Disease control measures in
Michigan included, among other policy changes, decreasing
deer density through increased hunting. Control and sur-
veillance measures have now been in place in Michigan for
over 10 years, and a significant reduction in apparent prev-
alence of tuberculosis in deer has been achieved (O’Brien
et al., 2006). However, public support for further popula-
tion reduction is waning (O’Brien et al., 2006). Vaccination
of deer in specific areas of sustained higher disease preva-
lence could be used to prevent infection, disease or trans-
mission. Recently, protection, in the form of decreased
disease severity, was demonstrated by subcutaneous (SC)
and oral vaccination of white-tailed deer with M. bovis
bacillus Calmette–Guerin (BCG) (Palmer et al., 2007, 2009;
Nol et al., 2008). These studies also demonstrated BCG
persistence within host tissue for up to 9 months after vac-
cination as well as shedding of viable BCG to non-vacci-
nated deer.
White-tailed deer hunters frequently consume venison
(Wilkins et al., 2003); consequently, the persistence of BCG
in vaccinated deer presents a potential public health con-
cern. Although BCG is generally considered avirulent for
immunocompetent humans, exposure to BCG could cause
false-positive responses to the tuberculin skin test, interfer-
ing with public tuberculosis surveillance efforts. Previous
studies have shown BCG persistence in white-tailed deer
for up to 3 and 9 months after oral or SC vaccination,
respectively (Palmer et al., 2010).
Lipid-formulated baits have been developed for oral
delivery of BCG. Lipid encapsulation protects viable BCG
from gastric degradation, allowing lipolytic enzymes of the
small and large intestines to liberate BCG, enhancing
uptake by gastrointestinal-associated lymphoid tissue
(GALT) (Aldwell et al., 2003b). Lipid-encapsulated BCG
delivered orally to brushtail possums (Trichosurus vulpecu-
la) persist in mesenteric lymphoid tissue of the GALT for
up to 8 weeks (Wedlock et al., 2005). Possums vaccinated
with lipid-encapsulated BCG shed viable vaccine in faeces
for up to 7 days after vaccination, but always in low num-
bers [<103 colony-forming units (CFU)/gm faeces] (Wed-
lock et al., 2005). Both vaccine persistence and shedding
are important as non-target species such as scavengers, pre-
dators and even cattle may be exposed to BCG in the envi-
ronment as well as persistent BCG in tissues. Experimental
vaccination and challenge studies in brushtail possums, a
wildlife reservoir host of M. bovis in New Zealand, showed
decreased weight loss, lower lung–body weight ratio, fewer
extrapulmonary lesions, and lower lung and spleen bacte-
rial counts in vaccinates compared to non-vaccinates
(Cross et al., 2009). Field vaccination studies, using lipid-
encapsulated BCG, show protection against natural infec-
tion with an estimated efficacy of 95–96% (Ramsey et al.,
2009; Tompkins et al., 2009). The objective of the present
study in white-tailed deer was to evaluate persistence of
lipid-encapsulated BCG after oral administration at two
different dosages, as well as a liquid suspension of BCG.
Materials and Methods
Vaccine
Mycobacterium bovis BCG Danish was used as the vaccine
strain. Bacteria were grown to mid-log phase in 175-ml
flasks (Falcon) containing Middlebrook 7H9 medium (Dif-
co, Detroit, MI, USA) supplemented with albumin–dex-
trose–catalase (Buddle et al., 1995). Bacilli were harvested
by centrifugation and washed twice in phosphate-buffered
saline (PBS), 0.01 M, pH 7.2, prior to storage at 70°C.
The CFU of BCG was determined retrospectively by plating
on 7H11 agar (Difco) supplemented with oleic acid–albu-
min–dextrose–catalase (Becton Dickinson, Cockeysville,
MD, USA) as described previously (Buddle et al., 1994).
Lipid composition
A fractionated lipid product was previously selected for
encapsulation of BCG on the basis of melting temperature
(32°C) and the ability to maintain bacilli in a viable and
uniform suspension as assessed by counting CFU (Aldwell
et al., 2003b). The lipid product consisted of triglycerides
of fatty acids comprising 1% myristic acid, 25% palmitic
acid, 15% stearic acid, 50% oleic acid and 6% linoleic acid
(Aldwell et al., 2003a,b).
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Lipid encapsulation of BCG
Glucose (10 mg/ml), monosodium glutamate (1 mg/ml;
Sigma-Aldrich, St. Louis, MO, USA) and 10% vol/vol albu-
min–dextrose–catalase were added to the lipid formulation.
These additives were dispersed with the lipid in the liquid
phase (40°C) and were previously shown not to affect BCG
viability. Pelleted BCG was resuspended in the liquefied
formulation medium that had been warmed to 40°C. The
BCG–lipid formulation was transferred to plastic moulds
and allowed to solidify with gentle mixing at 4°C. BCG–
lipid formulations were removed from the moulds as
required for viability testing and vaccination studies
(Aldwell et al., 2003a). A single lipid-encapsulated BCG
bait contained 1 9 108 CFU BCG.
For the liquid suspension vaccine, mid-log-phase growth
bacilli were pelleted by centrifugation at 750 9 g, washed
twice with PBS and diluted to the appropriate cell density
in 1.5 ml of PBS. Bacilli were enumerated by serial dilution
plate counting on 7H11 agar (Becton Dickinson) (Aldwell
et al., 2003a,b). A single vaccine dose consisted of
1 9 108 CFUM. bovis BCG in 1.5-ml PBS.
Vaccination of deer
Forty-five white-tailed deer (~1-year old, 23 females and 22
castrated males) were obtained either from a tuberculosis-
free captive breeding herd at the National Animal Disease
Center (Ames, Iowa, USA) or a private tuberculosis-free
captive deer facility. All deer were housed and cared for
according to institutional guidelines. Additionally, the
institutional animal care and use committee as well as the
institutional biosafety committee approved all procedures
prior to implementation. Deer were randomly assigned to
one of three groups of 15 deer each; single oral liquid sus-
pension of BCG, 1 9 108 CFU, (liquid group), single oral
lipid-encapsulated BCG bait, 1 9 108 CFU, (19 group)
and 10 oral lipid-encapsulated BCG baits; total dose
1 9 109 CFU (109 group). Delivery of the liquid suspen-
sion of BCG was carried out as previously described (Nol
et al., 2008). Lipid-encapsulated baits were offered to deer
while individually housed to ensure consumption. To
enhance palatability, baits were mixed with a small amount
of shelled corn and molasses.
Necropsy and sample collection
Three deer from each group were euthanized by IV sodium
pentobarbital and examined 1, 3, 6, 9 and 12 months after
vaccination. At necropsy, the following tissues were
collected: palatine tonsil, mandibular, parotid, medial ret-
ropharyngeal, tracheobronchial, mediastinal, hepatic, duo-
denal, proximal jejunal, middle jejunal, distal jejunal, ileal,
colic and iliac lymph nodes, and lung. All samples were
processed for isolation of BCG and microscopic analysis as
described (Palmer et al., 2002a,b; Hines et al., 2006). Tis-
sues collected for microscopic analysis were fixed by
immersion in 10% neutral buffered formalin, processed by
routine paraffin-embedment techniques, cut in 5 lm sec-
tions and stained with haematoxylin and eosin (HE). Adja-
cent sections were cut from samples containing lesions
suggestive of tuberculosis (granulomas) and stained by the
Ziehl–Neelsen technique for identification of acid-fast bac-
teria (AFB). For bacteriologic isolation of BCG, samples
were submitted pooled into four different groups: head
pool (palatine tonsil, mandibular, parotid and medial ret-
ropharyngeal lymph nodes), thoracic pool (tracheobron-
chial and mediastinal lymph nodes and lung), abdominal
pool (hepatic, duodenal, proximal jejunal, mid-jejunal, dis-
tal jejunal, ileal, colic and iliac lymph nodes) and muscle
pool (epaxial, sublumbar, supraspinatus, triceps, semi-
membranosus, semitendinosus and biceps femoris).
Isolation and identification of mycobacterial isolates
Tissues were processed for isolation of BCG as previously
described (Hines et al., 2006) using both the BACTEC 460
radiometric system and BACTEC Mycobacteria Growth
Indicator Tube (MGIT) 960 system (Becton Dickinson).
Isolates of BCG were identified by a combination of Ziehl–
Neelsen acid-fast staining, nucleic acid probes (AccuProbe,
Gen-Probe, San Diego, CA, USA), spoligotyping and a
BCG differential PCR described previously (Huard et al.,
2003). Further identification of atypical mycobacteria was
carried out using partial 16S ribosomal sequencing of the
ribosomal polymerase b-subunit as described previously
(Kierschner and Bottger, 1998; Ben Salah et al., 2008).
Sequences were then identified through use of a mycobac-
terial species sequence database and GenBank (Harmsen
et al., 2003).
Results
Mycobacterium bovis BCG was not isolated from any tissue
at any time point from deer consuming a single dose of
lipid-encapsulated BCG. However, BCG from the liquid
suspension vaccine was recovered from one of three deer
each at 1, 6 and 9 months after vaccination (Table 1). Per-
sistence of BCG was most consistent in deer consuming 10
lipid-encapsulated BCG baits (109 group). Mycobacterium
bovis BCG was recovered from at least one of three deer at
each time point, with BCG recovered from two of three
and three of three deer at 1 month and 6 months, respec-
tively, after vaccination.
Regardless of group, BCG was most commonly isolated
from the head and thoracic tissue pools with fewer
isolations from the abdominal tissue pool. Gross lesions
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suggestive of tuberculosis were not seen in any deer from
any group at any time point. Microscopic examination
revealed histocompatible lesions (granulomas with AFB) in
the middle jejunal lymph node of one deer in the 109 dose
group at 3 months after vaccination and the medial retro-
pharyngeal lymph node of a separate deer in the 109 dose
group at 9 months after vaccination. Lesions were charac-
terized by granulomas composed of epithelioid macrophag-
es, lymphocytes and multinucleated giant cells. Neither
central necrosis nor circumferential fibrosis was present.
Acid-fast bacteria were rare; nevertheless, when present,
they were found within multinucleated giant cells or mac-
rophages. In addition, from the deer with microscopic
lesions, BCG was isolated from the corresponding pools of
tissues, abdominal and head, respectively.
Ten different non-tuberculous mycobacteria (NTM),
atypical mycobacterial species or undetermined M. tb com-
plex species were isolated from deer in the current study
(Table 2). Bacteria of the Mycobacterium avium complex
(comprised of numerous subspecies ofM. avium andMyco-
bacteria intracellulare) were most frequently isolated fol-
lowed by Mycobacterium kansasii. Neither gross nor
microscopic lesions were present in tissues from which
NTM, atypical mycobacteria or undetermined mycobacte-
rial species were isolated. In 6 of 33 deer, both NTM and
BCG were isolated (Table 2). Non-tuberculous mycobacte-
ria were isolated from roughly equal numbers of deer in
each of the three treatment groups and at each time point
(data not shown).
Discussion
Persistence of BCG in vaccinated animals (deer and cattle)
is an important public safety concern as many such animals
are used for food. Few studies have examined the
persistence of BCG in food animals. Previously in red deer
(Cervus elaphus) vaccinated SC, BCG Pasteur was recovered
from 50% of vaccinates at the site of injection and associ-
ated lymph nodes 3 months after vaccination (Slobbe
et al., 1999). Importantly, quantitative bacteriological cul-
ture demonstrated that BCG was present in very small
numbers (i.e. approximately 0.1% of original vaccine dose)
(Slobbe et al., 1999). In white-tailed deer, BCG was recov-
erable up to 9 months after SC injection of 1 9 107 CFU
BCG Pasteur (Palmer et al., 2007). Similarly, persistence of
up to 9 months was documented in white-tailed deer vacci-
nated SC with 1 9 107 CFU of either Pasteur or Danish
strains of BCG. In a separate study, oral vaccination of
white-tailed deer with a liquid suspension of 1 9 109 CFU
BCG Danish resulted in persistence of up to 3 months (Pal-
mer et al., 2010). It is clear that BCG persistence should be
considered prior to field use in white-tailed deer.
Previously, oral dosing of BCG in liquid suspension
resulted in persistence of up to 3 months in white-tailed
deer (Palmer et al., 2010). Similar dosing (1 9 108 CFU)
in the present study resulted in persistence of up to
9 months. Additionally, in the present study, a greater dose
(1 9 109 CFU) of lipid-encapsulated BCG arising from
consumption of 10 BCG baits resulted in persistence of up
to 12 months. Persistence has also been demonstrated in
Table 1. Isolation of Mycobacterium bovis BCG from deer orally
vaccinated with a single dose (19, 1 9 108 CFU) or 10 doses
(109, 1 9 109 CFU) of a lipid-encapsulated BCG bait or a liquid
suspension of M. bovis BCG (Liquid, 1 9 108 CFU). Three deer each
were euthanized and examined at 1, 3, 6, 9 and 12 months after
vaccination
Months after Vaccination
Isolation of Mycobacterium bovis BCG
Group 1 3 6 9 12
19 Oral 0/3 0/3 0/3 0/3 0/3
109 Oral 2/3a 3/3b 1/3c 1/3d 1/3e
Liquid 1/3f 0/3 1/3g 1/3h 0/3
aIsolation of M. bovis BCG from head pool of one deer and abdominal
pool of a second deer.
bIsolation of M. bovis BCG from thoracic pool from two deer and head
pool from a third deer.
cIsolation of M. bovis BCG from head and abdominal pools and hepatic
lymph node.
dIsolation of M. bovis BCG from thoracic and abdominal pools.
eIsolation of M. bovis BCG from head and abdominal pools.
fIsolation ofM. bovis BCG from head pool.
gIsolation of M. bovis BCG from thoracic pool.
Table 2. Isolation of non-tuberculous (NTM) or atypical mycobacteria
from deer vaccinated orally with lipid-encapsulated Mycobacterium








Mycobacterium kansassi 9 3
Mycobacterium avium complex 7 1
Mycobacterium avium subsp. avium 1 0
Mycobacterium avium subsp. hominissuis 3 0
Mycobacterium intracellulare 4 0
Mycobacterium fortuitum 2 0
Unidentified mycobacterial species 3 0
Mycobacterium smegmatis 1 1
Mycobacterium chelonae 1 0
Mycobacterium setense 1 1
Undetermined Mycobacterium
tuberculosis complex (likely BCG)
1 0
aNumber of deer from which the isolate was obtained.
bNumber of deer from which both BCG and NTM or atypical isolates
were isolated.
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murine studies where oral vaccinates using non-encapsu-
lated BCG was 3 months (16/38 animals), while oral dosing
with lipid-encapsulated BCG demonstrated extended per-
sistence of up to 7.5 months in all (38/38) animals (Aldwell
et al., 2006). Of significant note is that some degree of per-
sistence is necessary to mount an effective immune
response to BCG vaccination as shown in murine studies
demonstrating that BCG persistence is vital in development
of lasting immunological memory (Olsen et al., 2004; Cross
et al., 2007). The ideal duration of persistence for maxi-
mum host protection and minimum risk to humans con-
suming BCG vaccinated food animals remains to be
determined.
Lipid formulation of BCG protects the live vaccine from
the harmful effects of the gastric environment (i.e. acidic
pH, enzymes), allowing viable BCG access to important
sites of intestinal mucosal immune induction (Aldwell
et al., 2006). Previous studies in brushtail possums
(Trichosurus vulpecula) showed the efficacy of BCG could
be improved by protection from gastric degradation
through lipid encapsulation or intraduodenal administra-
tion (Buddle et al., 1997). Thus far, most use of lipid-
encapsulated BCG has been in monogastric omnivorous
mammals such as the Eurasian badger (Meles meles) and
brushtail possum (Aldwell et al., 2003a, 2006; Cross et al.,
2009; Corner et al., 2010; Aznar et al., 2011). In contrast,
deer are herbivorous ruminants that ferment, absorb and
digest plant material in the rumen. The rumen contains a
complex resident microbiota of bacteria, protozoa, archaea
and fungi. In contrast to the monogastric stomach with a
pH < 4, the rumen has a pH of 5.5–6.5 and lacks digestive
enzymes of the stomach. The rumen therefore is a vastly
different environment than the monogastric stomach. The
effect of rumen environment on survivability of BCG is
unclear. Furthermore, ruminants regurgitate a food bolus
(cud) for rechewing. The process of repeated regurgitation
and rechewing is known as rumination. As orally vacci-
nated ruminants ruminate, oropharyngeal lymphoid tissue
(e.g. tonsils) may be repeatedly exposed to BCG. The effect
or importance of the rumen environment or multiple BCG
exposures on the immune response and host protection is
unclear.
In the present study, viable BCG was recovered with
equal frequency from the head and thoracic pools. Pooled
tissues from the head included mandibular, parotid and
medial retropharyngeal lymph nodes as well as palatine
tonsil. Mandibular, parotid and medial retropharyngeal
lymph nodes all receive afferent lymphatics from tissues of
the oral cavity (e.g. tongue, hard and soft palates, oral
mucosa and floor of the mouth). Additionally, the medial
retropharyngeal lymph node receives afferent lymphatics
from the tonsils (Saar and Getty, 1975). As tissues from the
head were pooled, it is not possible from the current study
to determine which of the pooled head tissues was most
commonly affected. However, it is clear that in naturally or
experimentally infected deer, the medial retropharyngeal
lymph node is the most common site for tuberculous lesion
development (Schmitt et al., 1997; Palmer et al., 1999,
2002a; O’Brien et al., 2001). Furthermore, M. bovis is
found, even in the absence of lesions, in 76% of palatine
tonsils from naturally infected animals that have tubercu-
lous lesions in one or more head lymph nodes (Palmer
et al., 2002c). Accordingly, it would be reasonable to
assume that isolation of BCG from the medial retropharyn-
geal lymph nodes and tonsils of orally vaccinated deer
would also be common.
Presence of BCG in thoracic samples suggests lymphatic
or haematogenous spread of BCG after oral vaccination.
Although BCG dissemination has been reported previously
in white-tailed deer (Palmer et al., 2010), such has not been
the case in studies of red deer or cattle (Griffin et al., 1993).
Moreover, neither gross nor microscopic lesions have been
associated with BCG vaccination studies in red deer or cat-
tle (Griffin et al., 1993).
The isolation of numerous NTM and atypical mycobac-
teria from white-tailed deer is consistent with previous
findings (Palmer et al., 1999, 2001, 2007, 2010). With the
exception of M. avium subsp. paratuberculosis (Mackintosh
et al., 2004) and rare cases of disease caused by M. avium
subsp. avium (de Lisle and Havill, 1985) or M. kansasii
(Hall et al., 2005), most NTM are considered non-patho-
genic in deer. The absence of lesions in NTM-infected
tissues in the present study would support their non-patho-
genic nature in white-tailed deer.
The presence and persistence of BCG in vaccinated deer
seemingly implies the potential for human exposure to
BCG through consumption of venison. Notwithstanding,
persistent BCG has only been found in lymphoid or intesti-
nal organs that are generally avoided as food. Conversely,
BCG has not been recovered from muscle (meat) samples
commonly consumed as food (Palmer et al., 2010). More-
over, surveys in Michigan, USA, show that the majority of
hunters cook venison prior to consumption (Wilkins et al.,
2003). Thorough cooking at 60°C for 6 min has been
shown to kill virulent M. bovis (Merkal and Whipple,
1980). Therefore, potential for human exposure to BCG
through venison consumption is low.
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